Bash C - Search Results

Year	Number of Results
1995	3
1996	2
1997	4
1998	3
2000	2
2001	1
2002	2
2004	1
2005	2
2006	1
2015	1
2016	1
2023	0

1

Schwartz PJ, Loe JA, Bash CN, Bove K, Turner EH, Frank JA, Wehr TA, Rosenthal NE. Schwartz PJ, et al. Among authors: bash cn. Psychiatry Res. 1997 Jul 4;74(3):151-7. doi: 10.1016/s0925-4927(97)00015-2. Psychiatry Res. 1997. PMID: 9255860

2

Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.

Stone LA, Cutter GR, Fisher E, Richert N, McCartin J, Ohayon J, Bash C, McFarland H. Stone LA, et al. Among authors: bash c. J Neuroimaging. 2016 May;26(3):296-302. doi: 10.1111/jon.12321. Epub 2015 Dec 21. J Neuroimaging. 2016. PMID: 26686343

3

MRI of silicone vitreous ocular implants with phantom correlation.

Bash C, Rothman M, Hamet M, Sorce D, Zoarski G, Mihara F, Numaguchi Y. Bash C, et al. Neuroradiology. 1995 May;37(4):313-6. doi: 10.1007/BF00588344. Neuroradiology. 1995. PMID: 7666969

4

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis.

Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Zipp F, et al. Among authors: bash cn. Ann Neurol. 1998 Jan;43(1):116-20. doi: 10.1002/ana.410430120. Ann Neurol. 1998. PMID: 9450777

5

MRI as a marker for disease heterogeneity in multiple sclerosis.

Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF. Bielekova B, et al. Among authors: bash cn. Neurology. 2005 Oct 11;65(7):1071-6. doi: 10.1212/01.wnl.0000178984.30534.f9. Neurology. 2005. PMID: 16217061

6

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.

Richert ND, Howard T, Frank JA, Stone R, Ostuni J, Ohayon J, Bash C, McFarland HF. Richert ND, et al. Among authors: bash c. Neurology. 2006 Feb 28;66(4):551-6. doi: 10.1212/01.wnl.0000197982.78063.06. Neurology. 2006. PMID: 16505310

7

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.

Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA. Richert ND, et al. Among authors: bash cn. Mult Scler. 2000 Apr;6(2):86-90. doi: 10.1177/135245850000600206. Mult Scler. 2000. PMID: 10773853 Clinical Trial.

8

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.

Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA. Rao AB, et al. Among authors: bash cn. Neurology. 2002 Sep 10;59(5):688-94. doi: 10.1212/wnl.59.5.688. Neurology. 2002. PMID: 12221158 Clinical Trial.

9

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.

Pulicken M, Bash CN, Costello K, Said A, Cuffari C, Wilterdink JL, Rogg JM, Mills P, Calabresi PA. Pulicken M, et al. Among authors: bash cn. Mult Scler. 2005 Apr;11(2):169-74. doi: 10.1191/1352458505ms1141oa. Mult Scler. 2005. PMID: 15794390 Clinical Trial.

10

ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions.

Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T, Maloni H, Jacobson S, McFarland HF. Calabresi PA, et al. Among authors: bash cn. J Neuroimmunol. 1998 May 15;85(2):212-9. doi: 10.1016/s0165-5728(98)00008-3. J Neuroimmunol. 1998. PMID: 9630170

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results